Allogene Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALLO research report →
Companywww.allogene.com
Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
- CEO
- David D. Chang
- IPO
- 2018
- Employees
- 226
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $458.21M
- P/E
- -2.60
- P/S
- 0.00
- P/B
- 1.62
- EV/EBITDA
- -3.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -56.45%
- ROIC
- -50.58%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-190,886,000 · 25.90%
- EPS
- $-0.87 · 34.09%
- Op Income
- $-206,933,000
- FCF YoY
- 25.55%
Performance & Tape
- 52W High
- $4.46
- 52W Low
- $0.98
- 50D MA
- $2.35
- 200D MA
- $1.66
- Beta
- 0.46
- Avg Volume
- 9.67M
Get TickerSpark's AI analysis on ALLO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 21, 26 | Yoshiyama Annie | sell | 9,586 |
| Mar 31, 26 | Beneski Benjamin Machinas | sell | 2,867 |
| Mar 16, 26 | Beneski Benjamin Machinas | sell | 4,835 |
| Mar 16, 26 | Chang David D | sell | 47,763 |
| Mar 2, 26 | Beneski Benjamin Machinas | sell | 7,132 |
| Feb 2, 26 | Beneski Benjamin Machinas | other | 373,757 |
| Feb 2, 26 | Beneski Benjamin Machinas | sell | 7,549 |
| Feb 2, 26 | Beneski Benjamin Machinas | other | 105,720 |
| Feb 2, 26 | Chang David D | sell | 95,269 |
| Feb 2, 26 | Chang David D | other | 1,387,931 |
Our ALLO Coverage
We haven't published any research on ALLO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALLO Report →